Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

West China Hospital50 enrolled

Overview

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sarcomatoid Carcinoma Liver Cancer Adjuvant Therapy

Interventions

postoperative adjuvant therapy

Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. patients who underwent liver resection 2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC Exclusion Criteria: 1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy; 2. patients diagnosed with other specific types of sarcomas; 3. patients with concurrent other malignancies during the course of PHSC; 4. patients who were lost to follow-up or lacked essential clinical data.

Outcomes

Primary Outcomes

Disease-free survival

Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.

Time frame: From December 2018 to May 2023

Secondary Outcomes

Overall survival

Overall survival (OS) was defined as the interval from liver resection to death or the last follow-up.